Endocannabinoid lipids and mediated system: Implications for alcoholism and neuropsychiatric disorders

Vinod, K. Yaragudri; Hungund, Basalingappa L.

doi:10.1016/j.lfs.2005.05.041

Cited by 32 publications

(19 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the mean time a second cannabinoid (CB2) receptor has been characterized and probably more receptors, including GPR55, will follow [2]. A significant body of evidence now suggests that the endocannabinoid system plays an essential role in many physiological processes, including energy metabolism and neurological functioning, and in several pathological conditions, including inflammation, cardiovascular diseases, cancer, neurological disorders, obesity, and the metabolic syndrome [3][4][5][6][7]. Anandamide (arachidonoyl ethanolamide, AEA) was the first endocannabinoid discovered.…”

Section: Introductionmentioning

confidence: 99%

Development and validation of a quantitative method for the determination of 12 endocannabinoids and related compounds in human plasma using liquid chromatography–tandem mass spectrometry

Balvers

Verhoeckx²,

Witkamp

2009

Journal of Chromatography B

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Development and validation of a quantitative method for the determination of 12 endocannabinoids and related compounds in human plasma using liquid chromatography–tandem mass spectrometry

Balvers

Verhoeckx²,

Witkamp

2009

Journal of Chromatography B

View full text Add to dashboard Cite

“…Mental Disorders. The well-known psychotropic effects of cannabinoids and the distribution of cannabinoid receptors across important emotional circuits in the brain suggest that the endocannabinoid system may be involved in various psychiatric disorders such as schizophrenia and mood disorders (reviewed in van der Stelt and Hall et al, 2004;Leweke et al, 2004;Manzanares et al, 2004;Ujike and Morita, 2004;Ashton et al, 2005;Gambi et al, 2005;Semple et al, 2005;Vinod and Hungund, 2005).…”

mentioning

confidence: 99%

The Endocannabinoid System as an Emerging Target of Pharmacotherapy

2006

View full text Add to dashboard Cite

“…-tetrahydrocannabinol (D 9 -THC) (Tanda and Goldberg, 2003), opiates (Fattore et al, 2004), nicotine (Cohen et al, 2005), and ethanol (Vinod and Hungund, 2005).…”

mentioning

confidence: 99%

Cannabinoid CB1 Receptor Antagonists Attenuate Cocaine's Rewarding Effects: Experiments with Self-Administration and Brain-Stimulation Reward in Rats

Spiller

Pak

et al. 2007

Neuropsychopharmacol

104

116

View full text Add to dashboard Cite

Previous studies suggest that cannabinoid CB1 receptors do not appear to be involved in cocaine's rewarding effects, as assessed by the use of SR141716A, a prototypic CB1 receptor antagonist and CB1-knockout mice. In the present study, we found that blockade of CB1 receptors by AM 251 (1-10 mg/kg), a novel CB1 receptor antagonist, dose-dependently lowered (by 30-70%) the break point for cocaine self-administration under a progressive-ratio (PR) reinforcement schedule in rats. The same doses of SR141716 (freebase form) maximally lowered the break point by 35%, which did not reach statistical significance. Neither AM 251 nor SR141716 altered cocaine self-administration under a fixed-ratio (FR2) reinforcement schedule. AM 251 (0.1-3 mg/kg) also significantly and dose-dependently inhibited (by 25-90%) cocaine-enhanced brain stimulation reward (BSR), while SR141716 attenuated cocaine's BSR-enhancing effect only at 3 mg/kg (by 40%). When the dose was increased to 10 or 20 mg/kg, both AM 251 and SR141716 became less effective, with AM 251 only partially inhibiting cocaine-enhanced BSR and PR cocaine self-administration, and SR141716 having no effect. AM 251 alone, at all doses tested, had no effect on BSR, while high doses of SR141716 alone significantly inhibited BSR. These data suggest that blockade of CB1 receptors by relatively low doses of AM 251 dose-dependently inhibits cocaine's rewarding effects, whereas SR141716 is largely ineffective, as assessed by both PR cocaine self-administration and BSR. Thus, AM 251 or other more potent CB1 receptor antagonists deserve further study as potentially effective anti-cocaine medications.

show abstract

Endocannabinoid lipids and mediated system: Implications for alcoholism and neuropsychiatric disorders

Cited by 32 publications

References 90 publications

Development and validation of a quantitative method for the determination of 12 endocannabinoids and related compounds in human plasma using liquid chromatography–tandem mass spectrometry

Development and validation of a quantitative method for the determination of 12 endocannabinoids and related compounds in human plasma using liquid chromatography–tandem mass spectrometry

The Endocannabinoid System as an Emerging Target of Pharmacotherapy

Cannabinoid CB1 Receptor Antagonists Attenuate Cocaine's Rewarding Effects: Experiments with Self-Administration and Brain-Stimulation Reward in Rats

Contact Info

Product

Resources

About